. 2022 Feb 8;32(5):1451–1458. doi: 10.1007/s11695-022-05955-8

Table 2.

PPIs consumption and de novo esophagitis after surgery

	Summary statistics	SG (n 140)	SG + RF (n 138)	p-value
Using PPIs	%, n/Pts	17.1%, 23/140	4.3%, 6/138	0.001*
EGDS Total esophagitis A esophagitis B esophagitis	N %, n/Pts %, n/Pts %, n/Pts	47 (33.6%) 23.4%, 11/47 54.5%, 6/11 45.5%, 5/11	50 (36.2%) 2.0%, 1/50 100%, 2/2 0%, 0/2	0.002*

Summary statistics

SG (n 140)

SG + RF (n 138)

p-value

Using PPIs

%, n/Pts

17.1%, 23/140

4.3%, 6/138

0.001*

EGDS

Total esophagitis

A esophagitis

B esophagitis

%, n/Pts

47 (33.6%)

23.4%, 11/47

54.5%, 6/11

45.5%, 5/11

50 (36.2%)

2.0%, 1/50

100%, 2/2

0%, 0/2

0.002*

SG sleeve gastrectomy; RF Rossetti fundoplication; PPIs proton pump inhibitor; EE erosive esophagitis; EGSD esophago-gastro-duodenoscopy; N number of patients analyzed when different from the total; n/Pts number of patients out of the total; *statistically significant